Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Omkar PharmachemBOM:532167 52 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates BOM:532167 with a GF Score™ of 52/100 and a GF Value™ of ₹23.90 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,070 Business Services companies, Omkar Pharmachem ranks worse than 93457.85% on this metric.
The historical rank and industry rank for Omkar Pharmachem's Net Margin % or its related term are showing as below:
BOM:532167's Net Margin % is not ranked *
in the Business Services industry.
Industry Median: 3.82 * Ranked among companies with meaningful Net Margin % only.
Omkar Pharmachem (BOM:532167) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Omkar Pharmachem Net Margin % Related Terms
Omkar Pharmachem Net Margin % Historical Data
* Premium members only.
The historical data trend for Omkar Pharmachem's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532167 vs CTAS, CPRT, GPN: Net Margin % Comparison
For the Specialty Business Services subindustry, Omkar Pharmachem's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omkar Pharmachem Net Margin % vs Business Services Industry
For the Business Services industry and Industrials sector, Omkar Pharmachem's Net Margin % distribution charts can be found below:
* The bar in red indicates where Omkar Pharmachem's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omkar Pharmachem (BOM:532167) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Omkar Pharmachem and its competitors. According to the industry distribution chart, Omkar Pharmachem ranks #999999 out of 1070 companies in the Business Services industry.
Is Omkar Pharmachem's Net Margin % too high?
Omkar Pharmachem's current Net Margin % is 0.00%. Based on the distribution chart, Omkar Pharmachem ranks #999999 out of 1070 companies in the Business Services industry, which is in the bottom quartile relative to peers. Overall, Omkar Pharmachem has a GF Score™ of 52/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Omkar Pharmachem's Net Margin % compare to CTAS and CPRT?
According to the Business Services industry distribution chart, Omkar Pharmachem ranks #999999 out of 1070 companies for Net Margin %. This places Omkar Pharmachem in the lower half of its industry. The industry median Net Margin % is 3.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Business Services company?
The median Net Margin % among Business Services companies is 3.82, based on 1,070 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Omkar Pharmachem and its competitors. For the Business Services industry, the median Net Margin % is 3.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omkar Pharmachem's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omkar Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Omkar Pharmachem (BOM:532167) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹23.90, compared to a current price of ₹16.30 — trading 31.8% below its estimated fair value. The current Net Margin % is 0.00%. Omkar Pharmachem's overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Omkar Pharmachem (BOM:532167), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omkar Pharmachem (BOM:532167) Overvalued in 2026?
Based on GuruFocus' analysis, Omkar Pharmachem stock appears to be undervalued.
The current stock price of ₹16.30 is trading 31.8% below its estimated GF Value™ of ₹23.90.
GuruFocus considers Omkar Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:532167:
Net Margin %: 0.00%
GF Value™: ₹23.90 vs. price of ₹16.30 (31.8% below fair value)
No single metric tells the full story. See the BOM:532167 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532167 has been successfully added to your 
